IDC 006
Alternative Names: IDC-006Latest Information Update: 26 Aug 2022
Price :
$50 *
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer; Gastric cancer
Most Recent Events
- 25 Jul 2022 Prestige Biopharma plans a phase I-III trials for Breast cancer and Gastric cancer in Singapore in 2027 (Prestige Biopharma website, July 2022)
- 20 Jul 2022 Prestige Biopharma plans a preclinical trials for Breast cancer and Gastric cancer in Singapore in 2024 (Prestige Biopharma website, July 2022)
- 20 Jul 2022 Early research in Breast cancer in Singapore (Parenteral) (Prestige Biopharma pipeline, July 2022)